INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.

On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.

Zhitong Finance20:24 ET

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China

PR Newswire18:55 ET

Express News | Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca

Reuters18:56 ET

Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50

Yahoo FinanceDec 14 08:05 ET

Why Is Eli Lilly and Company (LLY) Among the Best Income Stocks to Buy According to Analysts?

Yahoo FinanceDec 14 00:17 ET

Weekly Buzz: Tech stocks hit high scores on ominous day

Kevin TraversDec 13 16:29 ET